查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1291413

抗肥胖症藥物市場：2023-2028年全球行業趨勢、佔有率、規模、成長、機會和預測

Anti-Obesity Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

市場概況：

全球抗肥胖藥物市場規模在2022年達到20億美元。展望未來，IMARC Group預計到2028年，市場規模將達到40億美元，在2023-2028年期間表現出11.7%的成長率（CAGR）。

抗肥胖藥物的目的是減少或控制體重，一般只在病態肥胖的情況下進行醫療處方。它們有助於減少渴望和控制強迫性飲食，特別是對甜食和高脂肪、高鹽和高熱量食品的渴望。它們還能提供獨立的健康益處，如控制血壓、有害脂質水平、腰圍、糖分水平和非酒精性脂肪肝（NAFLD），並將主要心血管疾病（CVDs）和糖尿病腎病進展的風險降至最低。

抗肥胖症藥物的市場趨勢：

抗肥胖症藥物的最新進展使個人有可能獲得臨床上顯著的體重減輕。這與久坐不動的生活方式促使的肥胖症的廣泛流行相融合，是創造市場積極前景的關鍵因素之一。此外，肥胖增加了患2型糖尿病（T2D）、心血管疾病（CVD）以及食道、結腸和直腸、肝臟、膽囊、胰腺和腎臟癌症的風險。它還會促使許多心理、神經、肺、胃腸、腎、肌肉骨骼和內分泌疾病。除此之外，睡眠不足、晝夜不同步、長期壓力以及抗癲癇和精神藥物使用的增加，可能進一步誘發體重增加。再加上越來越多的有助於調節食慾和食物渴望的抗肥胖藥物（AOMs）獲得批准，正在推動市場的成長。除此以外，減肥有助於改善個人的生活品質、活動能力、日常功能和心理健康。這一點，再加上健康意識的增強，製藥業的蓬勃發展，以及對與體重過重密切相關的疾病管理的日益重視，預計將刺激市場的成長。

本報告回答的關鍵問題：

  • 2022年全球抗肥胖藥物市場的規模是多少？
  • 2023-2028年，全球抗肥胖藥物市場的預期成長率是多少？
  • 推動全球抗肥胖藥物市場的關鍵因素是什麼？
  • COVID-19對全球抗肥胖藥物市場的影響是什麼？
  • 全球抗肥胖藥物市場基於藥物類別的詳細情形是什麼？
  • 基於藥物類型的全球抗肥胖藥物市場的詳細情形如何？
  • 基於配銷通路的全球抗肥胖藥物市場的詳細情形如何？
  • 全球抗肥胖藥物市場的主要地區有哪些？
  • 誰是全球抗肥胖藥物市場的主要參與者/公司？

目錄

第一章：前言

第二章：範圍和方法

  • 研究的目標
  • 利益相關者
  • 數據來源
    • 主要來源
    • 二級來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第三章：執行摘要

第四章：簡介

  • 概述
  • 主要行業趨勢

第五章：全球抗肥胖症藥物市場

  • 市場概況
  • 市場表現
  • COVID-19的影響
  • 市場預測

第六章：按藥物類別分類的市場

  • 周邊作用藥物
    • 市場趨勢
    • 市場預測
  • 中樞作用藥物
    • 市場趨勢
    • 市場預測

第7章：按藥物類型分類的市場

  • 處方藥
    • 市場趨勢
    • 市場預測
  • 非處方藥
    • 市場趨勢
    • 市場預測

第8章：按配銷通路分類的市場

  • 醫院藥房
    • 市場趨勢
    • 市場預測
  • 零售藥店
    • 市場趨勢
    • 市場預測
  • 網上藥店
    • 市場趨勢
    • 市場預測

第九章：按地區分類的市場

  • 北美洲
    • 美國
      • 市場趨勢
      • 市場預測
    • 加拿大
      • 市場趨勢
      • 市場預測
  • 亞太地區
    • 中國
      • 市場趨勢
      • 市場預測
    • 日本
      • 市場趨勢
      • 市場預測
    • 印度
      • 市場趨勢
      • 市場預測
    • 韓國
      • 市場趨勢
      • 市場預測
    • 澳大利亞
      • 市場趨勢
      • 市場預測
    • 印尼
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 歐洲
    • 德國
      • 市場趨勢
      • 市場預測
    • 法國
      • 市場趨勢
      • 市場預測
    • 英國
      • 市場趨勢
      • 市場預測
    • 義大利
      • 市場趨勢
      • 市場預測
    • 西班牙
      • 市場趨勢
      • 市場預測
    • 俄羅斯
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場趨勢
      • 市場預測
    • 墨西哥
      • 市場趨勢
      • 市場預測
    • 其他國家
      • 市場趨勢
      • 市場預測
  • 中東和非洲
    • 市場趨勢
    • 按國家分類的市場
    • 市場預測

第十章：SWOT分析

  • 概述
  • 優勢
  • 劣勢
  • 機會
  • 威脅

第十一章：價值鏈分析

第十二章：波特五力分析

  • 概述
  • 買方的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第十三章：價格分析

第十四章：競爭格局

  • 市場結構
  • 主要參與者
  • 主要參與者的概況
    • Boehringer Ingelheim International GmbH
    • Currax Pharmaceuticals LLC
    • Gelesis
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Norgine BV
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Rhythm Pharmaceuticals Inc.
    • SHIONOGI & Co. Ltd.
    • Takeda Pharmaceutical Company Limited
    • Vivus LLC
Product Code: SR112023A5544

Market Overview:

The global anti-obesity drugs market size reached US$ 2.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2028, exhibiting a growth rate (CAGR) of 11.7% during 2023-2028.

Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.

Anti-Obesity Drugs Market Trends:

Recent advances in anti-obesity drugs have enabled the potential of attaining clinically significant weight loss among individuals. This, in confluence with the widespread prevalence of obesity on account of sedentary lifestyles, represents one of the key factors creating a positive outlook for the market. In addition, obesity increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases (CVD), and cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. It can also result in numerous psychological, neurological, pulmonary, gastrointestinal, renal, musculoskeletal, and endocrine diseases. Besides this, sleep deprivation, circadian desynchronization, chronic stress, and the rising use of anti-epileptic and psychotropic drugs may further induce weight gain. This, coupled with the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings, is fueling the growth of the market. Apart from this, weight loss aids in improving the quality of life, mobility, daily function, and psychological well-being of individuals. This, along with the increasing health consciousness, thriving pharmaceutical industry, and the rising focus on the management of diseases closely integrated with excess body weight, is anticipated to stimulate the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-obesity drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, drug type and distribution channel.

Breakup by Drug Class:

  • Peripherally Acting Drugs
  • Centrally Acting Drugs

Breakup by Drug Type:

  • Prescription Drugs
  • OTC Drugs

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.

Key Questions Answered in This Report:

  • What was the size of the global anti-obesity drugs market in 2022?
  • What is the expected growth rate of the global anti-obesity drugs market during 2023-2028?
  • What are the key factors driving the global anti-obesity drugs market?
  • What has been the impact of COVID-19 on the global anti-obesity drugs market?
  • What is the breakup of the global anti-obesity drugs market based on the drug class?
  • What is the breakup of the global anti-obesity drugs market based on the drug type?
  • What is the breakup of the global anti-obesity drugs market based on distribution channel?
  • What are the key regions in the global anti-obesity drugs market?
  • Who are the key players/companies in the global anti-obesity drugs market?

Table of Contents

1   Preface

2   Scope and Methodology

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Anti-Obesity Drugs Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Drug Class

  • 6.1  Peripherally Acting Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2  Centrally Acting Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7   Market Breakup by Drug Type

  • 7.1  Prescription Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  OTC Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8   Market Breakup by Distribution Channel

  • 8.1  Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2  Retail Pharmacy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3  Online Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9   Market Breakup by Region

  • 9.1  North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2  Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3  Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4  Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5  Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10  SWOT Analysis

  • 10.1  Overview
  • 10.2  Strengths
  • 10.3  Weaknesses
  • 10.4  Opportunities
  • 10.5  Threats

11  Value Chain Analysis

12  Porters Five Forces Analysis

  • 12.1  Overview
  • 12.2  Bargaining Power of Buyers
  • 12.3  Bargaining Power of Suppliers
  • 12.4  Degree of Competition
  • 12.5  Threat of New Entrants
  • 12.6  Threat of Substitutes

13  Price Analysis

14  Competitive Landscape

  • 14.1  Market Structure
  • 14.2  Key Players
  • 14.3  Profiles of Key Players
    • 14.3.1  Boehringer Ingelheim International GmbH
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2  Currax Pharmaceuticals LLC
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3  Gelesis
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4  GlaxoSmithKline plc
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5  Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6  Norgine B.V.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7  Novo Nordisk A/S 
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8  Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9  Rhythm Pharmaceuticals Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10  SHIONOGI & Co. Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11  Takeda Pharmaceutical Company Limited
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12  Vivus LLC
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Anti-Obesity Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Obesity Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Anti-Obesity Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Anti-Obesity Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 5: Global: Anti-Obesity Drugs Market: Breakup by Drug Type (in %), 2022
  • Figure 6: Global: Anti-Obesity Drugs Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Anti-Obesity Drugs Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Anti-Obesity Drugs (Peripherally Acting Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Anti-Obesity Drugs (Centrally Acting Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Anti-Obesity Drugs (Prescription Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Anti-Obesity Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Anti-Obesity Drugs (OTC Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Anti-Obesity Drugs (OTC Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Anti-Obesity Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Anti-Obesity Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Anti-Obesity Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Anti-Obesity Drugs (Online Pharmacy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Anti-Obesity Drugs (Online Pharmacy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: North America: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: North America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: United States: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: United States: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Canada: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Canada: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Asia-Pacific: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Asia-Pacific: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: China: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: China: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Japan: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Japan: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: India: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: India: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: South Korea: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: South Korea: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Australia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Australia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Indonesia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Indonesia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Europe: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Europe: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Germany: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Germany: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: France: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: France: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: United Kingdom: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: United Kingdom: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Italy: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Italy: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Spain: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Spain: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Russia: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Russia: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Latin America: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Latin America: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Brazil: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Brazil: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Mexico: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Mexico: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Others: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Others: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Middle East and Africa: Anti-Obesity Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Middle East and Africa: Anti-Obesity Drugs Market: Breakup by Country (in %), 2022
  • Figure 70: Middle East and Africa: Anti-Obesity Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Global: Anti-Obesity Drugs Industry: SWOT Analysis
  • Figure 72: Global: Anti-Obesity Drugs Industry: Value Chain Analysis
  • Figure 73: Global: Anti-Obesity Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Obesity Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Anti-Obesity Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 4: Global: Anti-Obesity Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Anti-Obesity Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Anti-Obesity Drugs Market: Competitive Structure
  • Table 7: Global: Anti-Obesity Drugs Market: Key Players